,address1,city,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,33 rue Marbeuf,Paris,75008,France,33 1 85 34 77 70,https://www.quantum-genomics.com,Biotechnology,Healthcare,"Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.",10,"{'maxAge': 1, 'name': 'Dr. Jean-Philippe  Milon Ph.D.', 'age': 62, 'title': 'CEO, MD & Chairman', 'yearBorn': 1960, 'fiscalYear': 2021, 'totalPay': 415825, 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.137,0.14,0.14,0.147,0.137,0.14,0.14,0.147,0.0,0.156531,-0.37837836,24315,24315,80415,26894,26894,0.0,0.0,0,0,5110266,0.0882,4.32,2.0318625,0.150828,0.1530965,0.0,0.0,EUR,-2487442,0.0,26892709,34763700,0.12773,0.1267,0.104,1.3461539,1672444800,1703980800,1672444800,-24935500,-0.8,-0.37,1:18,1386892800,-0.989,0.083,PAR,EQUITY,ALQGC.PA,ALQGC.PA,QUANTUM GENOMICS,Quantum Genomics Société Anonyme,1275030000,Europe/Paris,CEST,7200000,0.14,10.0,0.2,6.4,9.0,5.0,sell,3,10400763,0.298,-29819394,3033623,1.325,1.33,2515065,84.09,0.072,-0.8375,-3.75687,-26987257,-15726947,-20212736,-0.883,0.0,0.0,-11.96119,EUR,
1,33 rue Marbeuf,Paris,75008,France,33 1 85 34 77 70,https://www.quantum-genomics.com,Biotechnology,Healthcare,"Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.",10,"{'maxAge': 1, 'name': 'Mr. Benoît  Gueugnon', 'title': 'Admin. & Financial Director, VP of Fin. and CFO', 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.137,0.14,0.14,0.147,0.137,0.14,0.14,0.147,0.0,0.156531,-0.37837836,24315,24315,80415,26894,26894,0.0,0.0,0,0,5110266,0.0882,4.32,2.0318625,0.150828,0.1530965,0.0,0.0,EUR,-2487442,0.0,26892709,34763700,0.12773,0.1267,0.104,1.3461539,1672444800,1703980800,1672444800,-24935500,-0.8,-0.37,1:18,1386892800,-0.989,0.083,PAR,EQUITY,ALQGC.PA,ALQGC.PA,QUANTUM GENOMICS,Quantum Genomics Société Anonyme,1275030000,Europe/Paris,CEST,7200000,0.14,10.0,0.2,6.4,9.0,5.0,sell,3,10400763,0.298,-29819394,3033623,1.325,1.33,2515065,84.09,0.072,-0.8375,-3.75687,-26987257,-15726947,-20212736,-0.883,0.0,0.0,-11.96119,EUR,
2,33 rue Marbeuf,Paris,75008,France,33 1 85 34 77 70,https://www.quantum-genomics.com,Biotechnology,Healthcare,"Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.",10,"{'maxAge': 1, 'name': 'Dr. Bruno  Besse', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.137,0.14,0.14,0.147,0.137,0.14,0.14,0.147,0.0,0.156531,-0.37837836,24315,24315,80415,26894,26894,0.0,0.0,0,0,5110266,0.0882,4.32,2.0318625,0.150828,0.1530965,0.0,0.0,EUR,-2487442,0.0,26892709,34763700,0.12773,0.1267,0.104,1.3461539,1672444800,1703980800,1672444800,-24935500,-0.8,-0.37,1:18,1386892800,-0.989,0.083,PAR,EQUITY,ALQGC.PA,ALQGC.PA,QUANTUM GENOMICS,Quantum Genomics Société Anonyme,1275030000,Europe/Paris,CEST,7200000,0.14,10.0,0.2,6.4,9.0,5.0,sell,3,10400763,0.298,-29819394,3033623,1.325,1.33,2515065,84.09,0.072,-0.8375,-3.75687,-26987257,-15726947,-20212736,-0.883,0.0,0.0,-11.96119,EUR,
3,33 rue Marbeuf,Paris,75008,France,33 1 85 34 77 70,https://www.quantum-genomics.com,Biotechnology,Healthcare,"Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.",10,"{'maxAge': 1, 'name': 'Dr. Sarah  Merlen-Boulenger', 'title': 'Head of Regulatory Affairs', 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.137,0.14,0.14,0.147,0.137,0.14,0.14,0.147,0.0,0.156531,-0.37837836,24315,24315,80415,26894,26894,0.0,0.0,0,0,5110266,0.0882,4.32,2.0318625,0.150828,0.1530965,0.0,0.0,EUR,-2487442,0.0,26892709,34763700,0.12773,0.1267,0.104,1.3461539,1672444800,1703980800,1672444800,-24935500,-0.8,-0.37,1:18,1386892800,-0.989,0.083,PAR,EQUITY,ALQGC.PA,ALQGC.PA,QUANTUM GENOMICS,Quantum Genomics Société Anonyme,1275030000,Europe/Paris,CEST,7200000,0.14,10.0,0.2,6.4,9.0,5.0,sell,3,10400763,0.298,-29819394,3033623,1.325,1.33,2515065,84.09,0.072,-0.8375,-3.75687,-26987257,-15726947,-20212736,-0.883,0.0,0.0,-11.96119,EUR,
